A new randomized Tourette syndrome medication study just dropped on Ecopipam. Spoiler alert: It targeted D1 dopamine receptors and not D2 receptors and weight gain, sedation and movements were all less. New phase 3 randomized clinical trial for Tourette syndrome.
cutt.ly/ItM8r7aX
